Last reviewed · How we verify
NCT05701332
Effect of Intravesical B.C.G and Gemcitabine on Semen Quality and Testicular Volume
Phase 4 trial testing Bacillus Calmette Guerin in Urothelial Carcinoma Bladder in 25 participants. Status unknown.
1 December 2025
Quick facts
| Lead sponsor | Assiut University |
|---|---|
| Phase | Phase 4 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 25 |
| Start date | 1 April 2023 |
| Primary completion | 1 December 2025 |
| Estimated completion | 31 December 2025 |
Drugs / interventions tested
- Bacillus Calmette Guerin
Conditions studied
- Urothelial Carcinoma Bladder — all drugs for Urothelial Carcinoma Bladder →
- Sperm Count, Low — all drugs for Sperm Count, Low →
- Testis; Fibrosis — all drugs for Testis; Fibrosis →
Sponsor
Assiut University
Who can join
Adults 20 to 60, male only, with Urothelial Carcinoma Bladder or Sperm Count, Low. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To evaluate the effects of local intravesical B.C.G and gemcitabine on semen quality and testicular volume.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05701332
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Bacillus Calmette Guerin
Trials testing the same drug.
- NCT04806178 — Immunological Response of Bladder Cancer Patients Under BCG · Phase 3 · completed
Other recruiting trials for Urothelial Carcinoma Bladder
Currently open trials in the same condition.
- NCT03185468 — Intervention of Bladder Cancer by CAR-T · Phase 1, PHASE2 · recruiting
- NCT06983210 — Clinical Trial of AM80 in Combination With Gemcitabine, Cisplatin, and Nivolumab in Patients With Urothelial Carcinoma · Phase 2 · recruiting
- NCT06714617 — Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors · Phase 1 · active not recruiting
- NCT06806059 — Preoperative Physical Activity Before Radical Cystectomy and the Impact on Morbidity · NA · recruiting
- NCT06444815 — A Study of VET3-TGI in Patients With Solid Tumors · Phase 1 · recruiting
Other Assiut University trials
Trials by the same sponsor.
- NCT07423312 — Lead Exposure and Multiple Sclerosis · not yet recruiting
- NCT07234526 — Usage of Glucose Fluctuations as a Prognostic Marker in Septic Shock Patients · not yet recruiting
- NCT07273214 — Knowledge, Attitude and Practice of Third Trimester Pregnant Mothers Towards Self-Medication in Assiut, Egypt · not yet recruiting
- NCT07194863 — Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD · not yet recruiting
- NCT07053709 — Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05701332 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Assiut University
- Last refreshed: 27 January 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05701332.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing